Evidence map›Paper›PMID 24649303›Full record

ArticleMolecular and clinical oncology2014

Retrospective analysis of large-scale research screening of construction workers for the early diagnosis of mesothelioma.

Tomoko Hirohashi, Kiyoko Igarashi, Masaaki Abe, Masahiro Maeda, Okio Hino

Open access · bronzeAbstract read
In one paragraph

Article in Molecular and clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Pleural mesothelioma.Nature reviews. Disease primers · 2025
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Tomoko HirohashiDepartment of Pathology and Oncology, School of Medicine, Juntendo University, Bunkyo-Ku, Tokyo 113-8421;
Kiyoko IgarashiByotai-seiri Laboratory, Itabashi-Ku, Tokyo 173-0025;
Masaaki AbeDepartment of Pathology and Oncology, School of Medicine, Juntendo University, Bunkyo-Ku, Tokyo 113-8421;
Masahiro MaedaImmuno-Biological Laboratories, Co., Ltd., Fujioka-Shi, Gunma 375-0005, Japan.
Okio HinoDepartment of Pathology and Oncology, School of Medicine, Juntendo University, Bunkyo-Ku, Tokyo 113-8421;
Juntendo University · JPMedical & Biological Laboratories (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The early diagnosis of mesothelioma, an aggressive malignant tumor, is considered to be important for prognosis. X-ray is commonly used for the assessment of a mass in a population exhibiting a risk factor. However, there are currently no available studies indicating that such an assessment may be used to achieve early diagnosis and improve the patient's outcome. We previously reported that N-ERC/mesothelin may be a useful blood tumor marker for mesothelioma. In order to investigate whether this tumor marker is useful for early diagnosis in a mass examination, in 2007 we initiated a 5-year large-scale screening of construction workers with a risk of asbestos exposure in Japan. Blood samples were collected annually and N-ERC/mesothelin levels were determined. Based on the results of those findings, along with medical history and related data, we screened the participants to identify a high-risk population. As a result, 62 subjects were identified among ~40,000 participants as the high-risk population. Two of these 62 participants subsequently developed mesothelioma, although the remaining participants have not yet developed mesothelioma. In conclusion, N-ERC/mesothelin may be useful as a blood tumor marker in the early diagnosis of mesothelioma in a mass examination. A future prospective study to confirm the findings of this research screening is currently under planning.

Indexed as

early diagnosislarge-scale research screeningmesothelioma

Identifiers

PMID24649303
PMCPMC3915274
OpenAlexW1984100894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.